GLP-1 Receptor Agonists in Obstructive Sleep Apnea: A Propensity Score-Matched Real-World Analysis
A major retrospective study of nearly 900,000 patients suggests that GLP-1 receptor agonists may substantially lower the risk of stroke, hospitalization, and death in people with obstructive sleep apnea. The findings, published in Respiratory Medicine, offer the first large-scale real-world glimpse at the potential cerebrovascular and survival benefits of incretin-based therapies in this population.
What They Found
Researchers from the Mayo Clinic, West Virginia University, Johns Hopkins, Yale, and other institutions analyzed data from the TriNetX US Collaborative Network, a federated electronic health record database covering more than 100 million patients. The retrospective cohort study included adults diagnosed with obstructive sleep apnea between January 1, 2016, and December 31, 2025. After propensity score matching at a 1:1 ratio, the final analytic sample comprised 438,844 patients who received a GLP-1 receptor agonist and 438,844 matched controls who did not.
Patients were followed for up to five years across five key outcomes: ischemic stroke, intracranial hemorrhage, emergency department visits, inpatient hospitalizations, and all-cause mortality. The results were statistically significant across every endpoint at every time point (all p < 0.001).
The most striking finding was in all-cause mortality. At one year, patients treated with a GLP-1 receptor agonist had a 62 percent lower risk of death compared with matched controls (HR 0.38). This protective association remained robust at three years (HR 0.49) and five years (HR 0.54), suggesting a durable survival benefit.
The reduction in intracranial hemorrhage risk was similarly dramatic: a 56 percent lower hazard at one year (HR 0.44), 44 percent at three years (HR 0.56), and 39 percent at five years (HR 0.61). For ischemic stroke, the risk reductions were more modest but still clinically meaningful: 25 percent at one year (HR 0.75), 17 percent at three years (HR 0.83), and 13 percent at five years (HR 0.87).
Healthcare utilization outcomes also improved significantly. Patients on GLP-1 receptor agonists had 41 percent fewer inpatient hospitalizations at one year (HR 0.59), with the benefit attenuating slightly but persisting at three years (HR 0.67) and five years (HR 0.69). Emergency department visits were reduced by 23 percent at one year (HR 0.77), 14 percent at three years (HR 0.86), and 13 percent at five years (HR 0.87).
The authors reported that results were directionally consistent in prespecified subgroup analyses restricted to patients on CPAP therapy and in a separate analysis limited to tirzepatide, the newer dual GIP/GLP-1 receptor agonist.
Why It Matters
Obstructive sleep apnea affects an estimated one billion people worldwide and is independently associated with an elevated risk of cardiovascular disease, stroke, and premature mortality. The standard of care (positive airway pressure therapy) effectively treats the mechanical obstruction but does not directly address the underlying metabolic and inflammatory pathways that may drive adverse cardiovascular outcomes in these patients.
GLP-1 receptor agonists, originally developed for type 2 diabetes, have emerged over the past half-decade as powerful therapies for obesity and cardiovascular risk reduction. The Semaglutide and Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial demonstrated a 20 percent reduction in major adverse cardiovascular events with semaglutide in patients without diabetes. However, obstructive sleep apnea has received comparatively little attention in the GLP-1 outcomes literature, and no large-scale real-world study had examined the association between these medications and sleep apnea-related complications.
This study addresses that gap with data from routine clinical practice across a diverse U.S. population. If confirmed prospectively, the findings suggest that GLP-1 receptor agonists could serve as an important adjunct to standard OSA management, particularly in patients with obesity, a comorbidity present in the majority of sleep apnea cases. The medications may reduce cardiovascular risk through multiple mechanisms: weight loss, improved glycemic control, anti-inflammatory effects, and direct effects on vascular endothelium.
The magnitude of the mortality reduction (62 percent at one year) is notable and warrants careful scrutiny. While residual confounding is possible in any observational study, the consistency of the signal across all five outcomes and all three time points strengthens the case for a genuine protective effect.
Limits
The study has important limitations. As a retrospective observational analysis, it can demonstrate association but not causation. Propensity score matching reduces but cannot eliminate confounding by indication: patients who receive GLP-1 receptor agonists may differ systematically from those who do not in ways that are not captured in the electronic health record.
The TriNetX platform, while vast, draws from a network of U.S. health care organizations and may not generalize to other populations or health systems. The study did not report on adherence to GLP-1 therapy (patients may have initiated and discontinued treatment at various points), and it did not examine dose-response relationships. The authors also note that data on body mass index, a critical confounder, were missing for a substantial proportion of patients.
The one-year effect sizes are notably larger than those observed at five years, raising questions about whether the benefits attenuate over time, whether early survivors differ from later ones in clinically meaningful ways, or whether treatment discontinuation rates increase with follow-up duration.
Finally, the study did not assess OSA-specific outcomes such as apnea-hypopnea index, oxygen desaturation indices, or sleep quality, leaving open the question of whether GLP-1 receptor agonists improve the underlying sleep disorder or simply mitigate its downstream consequences.
Bottom Line
This large, propensity score-matched analysis from a national U.S. database found that GLP-1 receptor agonist use in patients with obstructive sleep apnea was associated with substantially lower risks of ischemic stroke, intracranial hemorrhage, emergency visits, inpatient admissions, and all-cause mortality at one, three, and five years of follow-up. The results, while hypothesis-generating, are consistent with a growing body of evidence that incretin-based therapies confer cardiovascular and survival benefits that extend beyond their metabolic effects.
For clinicians managing patients with obstructive sleep apnea and obesity, these data provide additional support for considering GLP-1 receptor agonists as part of a comprehensive treatment strategy. The findings also underscore the need for prospective randomized trials specifically designed to evaluate the cardiocerebrovascular effects of these medications in the sleep apnea population.
Source
Rai P, Sanghavi DK, Bhandari R, et al. “GLP-1 Receptor Agonists and Outcomes in Patients with Obstructive Sleep Apnea: A Propensity Score-Matched Analysis.” Respiratory Medicine, June 26, 2026. PMID: 42362122. doi: 10.1016/j.rmed.2026.109001.